MaxCyte, Inc. (MXCT)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Revenue
- 33,026,000 -14.5%
- Net income
- -44,630,000
- Gross profit
- 26,804,000
- Operating income
- -51,897,000
- Earnings per share
- -0.42
- R&D expense
- 20,823,000
Growth and profitability
- Gross margin
- 81.16
- Operating margin
- -157.14
- Net margin
- -135.14
- Return on equity
- -26.02
- Return on assets
- -22.04
- Free cash flow margin
- -109.54
Balance sheet
- Total assets
- 202,507,000
- Total liabilities
- 31,017,000
- Shareholders' equity
- 171,490,000
- Cash and equivalents
- 20,065,000
- Current ratio
- 8.30
Cash flow and ratios
- Operating cash flow
- -34,410,000
- Free cash flow
- -36,178,000
Shareholder returns
- Shares outstanding
- 103,250,292
- Book value per share
- 1.66
Company information
- Headquarters
- Rockville, MD
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Services-Commercial Physical & Biological Research
Fiscal year end: · Source: SEC EDGAR
MaxCyte, Inc. trades on NASDAQ under the ticker symbol MXCT. This page brings together its price chart, company profile, key financial figures and technical indicators.